Fmr LLC grew its stake in AC Immune SA (NASDAQ:ACIU) by 7.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,612,759 shares of the company’s stock after purchasing an additional 403,086 shares during the period. Fmr LLC owned about 8.52% of AC Immune worth $53,039,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Barclays PLC grew its position in AC Immune by 726.2% in the 4th quarter. Barclays PLC now owns 6,378 shares of the company’s stock worth $61,000 after purchasing an additional 5,606 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in AC Immune in the 4th quarter worth $121,000. Marshall Wace LLP acquired a new stake in AC Immune in the 3rd quarter worth $107,000. GSA Capital Partners LLP acquired a new stake in AC Immune in the 3rd quarter worth $110,000. Finally, JPMorgan Chase & Co. bought a new position in shares of AC Immune during the 3rd quarter worth about $142,000. Institutional investors own 29.97% of the company’s stock.
ACIU has been the subject of a number of analyst reports. UBS Group initiated coverage on shares of AC Immune in a report on Friday, January 4th. They set a “buy” rating and a $16.00 price objective for the company. BidaskClub downgraded shares of AC Immune from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 5th. Zacks Investment Research raised shares of AC Immune from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Wednesday, February 6th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of AC Immune in a report on Thursday, January 24th. Finally, ValuEngine downgraded shares of AC Immune from a “hold” rating to a “sell” rating in a report on Monday, March 25th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $12.35.
NASDAQ:ACIU opened at $4.95 on Wednesday. AC Immune SA has a 52 week low of $3.25 and a 52 week high of $17.40.
AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.77). The business had revenue of $1.41 million for the quarter, compared to the consensus estimate of $56.97 million. AC Immune had a negative return on equity of 33.97% and a negative net margin of 706.11%. As a group, equities research analysts expect that AC Immune SA will post 0.75 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2019/04/17/ac-immune-sa-aciu-shares-bought-by-fmr-llc.html.
AC Immune Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Featured Article: Cost of equity and a company’s balance sheet
Want to see what other hedge funds are holding ACIU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AC Immune SA (NASDAQ:ACIU).
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.